RVTY
Revvity, Inc.
September 15, 2026 · intraday
- Rarity
- 1.99
- Peak move
- +9.03%
- Float cap
- $14.4B
Revvity, Inc. provides health science solutions, technologies, expertise, and services that support workflows from discovery to development and diagnosis to cure. It operates in Life Sciences and Diagnostics, offering reagents, assays, software, and services for cell, gene, and protein research. Its customers include global pharmaceutical, biotechnology, and contract research organizations, as well as academic and government institutions.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the move- Key event
reg_fd_disclosureAt the 2026 Global Healthcare Conference, Revvity's Steve Willoughby said Q2 2025 revenue, organic growth and margins beat internal plans, diagnostics grew 11% organically with full-year guidance raised to high single digits, and the instrument backlog is the strongest in three to five years with book-to-bill above 1.0.
- Key event
policy_changeUKRI announced over £162 million in funding for two UK research institutes: £67.7 million for the Rosalind Franklin Institute and £95 million for the Henry Royce Institute.
- Key event
peer_disclosureWaters Corporation announced the global commercial launch of the BD FACSDiscover A7 Cell Analyzer, a spectral flow cytometer with FACSTruQ calibration technology, expanding its FACSDiscover cytometry platform into academia, pharma and CRO labs.
peer_disclosureChina's MGI (BGI) signed a strategic cooperation agreement with BioMap to jointly build dedicated cell foundation models and high-quality data infrastructure for virtual cell and virtual perturbation research.
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference on Sept 14, 2026, Revvity CFO Max Krakowiak discussed AI demand and margin expansion, the Human Cell Design acquisition, plans to sell its China immunodiagnostics business by end-2027 while retaining a minority stake and commercial rights, and a 6%-8% long-range organic growth target with operating margin reaching the upper-20s in 2026.